Looking at Anges CLI conditional approval, you will see the following couple statements. Imagine that. A CLI therapy could be available in Israel, while we wait until sometime before 1h20 to see interim results.
“Based on the agreed terms, Kamada will exclusively commercialize this HGF gene therapy drug for critical limb ischemia in Israel after obtaining regulatory approval in Japan and in Israel.”
“We already have an exclusive partnership with Mitsubishi Tanabe Pharmaceuticals for the sales and distribution of our HGF gene therapy drug for peripheral artery diseases including CLI in Japan and in USA.”
Market Data 
Markets 
AI
